Celu­lar­i­ty emerges from SPAC merg­er dou­bled down on cell ther­a­pies as Bob Hariri down­grades ill-fat­ed Covid-19 pro­gram

It took a few months longer than ex­pect­ed, but Bob Hariri has fi­nal­ly guid­ed Celu­lar­i­ty and its pla­cen­tal-de­rived cells to Wall Street.

Merg­ing with GX Ac­qui­si­tion Corp gives Celu­lar­i­ty $138 mil­lion to work with as Hariri push­es the NK cell and T cell ther­a­pies deep­er in­to ear­ly-stage tri­als.

The biotech, which has drawn at­ten­tion for a high-pro­file ef­fort to test an NK cell in­fu­sion ear­ly in the pan­dem­ic, has all but thrown in the tow­el on Covid-19, pri­or­i­tiz­ing in­stead can­cer in­di­ca­tions such as acute myeloid leukemia and glioblas­toma mul­ti­forme — con­form­ing clos­er to its peers in cell ther­a­py.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN